Introduction
Five Cents takes on Spanish Startups Trying to Change Everything by looking past the hype: rockets, gene therapies, EV charging, business software, food, travel platforms, and AI efficiency. The question is not who has raised the most money. It’s what each company still has to prove before it can genuinely reshape an industry. Start with that distinction, because it changes how every startup story should be read.
A startup can be Spanish-founded
A startup can be Spanish-founded, or built around Spain’s research and entrepreneurial ecosystem, while operating globally, using foreign capital, or even a foreign legal structure.
More importantly, these companies are making very different bets. PLD Space is building physical launch infrastructure. SpliceBio is working on a scientific platform. Wallbox combines hardware with energy software. Factorial and Perk are trying to become the software layer beneath everyday business operations. Heura depends on consumer habits, while Multiverse Computing needs technical performance to translate into customer value.
The first big test is whether an invention can become a repeatable service. PLD Space, based in Elche, has already achieved a major technical milestone, with its MIURA 1 test rocket reaching space. Its next challenge, MIURA 5, is much harder: putting small satellites into orbit reliably, at a competitive price, and often enough to build a real launch business.
Its public financing and roughly one hundred and seventy million euros in total funding show strategic backing and the capacity to keep building. They do not prove commercial economics. Small satellite operators can also buy cheaper shared rides on larger rockets. So PLD Space needs cadence, reliability, and contracts, not just another impressive launch.
SpliceBio faces an even sharper version of the proof problem. The Barcelona company is developing a gene-therapy approach for diseases involving genes too large for standard delivery vectors. Its method aims to send genetic pieces into cells, where they can join and make a functional protein. That is a serious scientific proposition, and its lead programme for Stargardt disease has entered clinical development. But a one-hundred-and-thirty-five-million-dollar Series B is not evidence that patients will benefit.
The decisive milestones are safety
The decisive milestones are safety, durable effect, manufacturing quality, and clinical results that hold up across the right patient group. In biotech, elegant science can still fail at the bedside. Wallbox shows why product adoption and financial health must be kept separate. The company has sold more than one-point-five million chargers, according to its own figures. Its broader ambition is compelling: make an EV charger part of a smarter energy system, able to manage demand and potentially send power back to a building or grid.
Yet charging hardware is competitive, margins can be thin, and public networks need utilisation and maintenance. Wallbox has also been negotiating new capital arrangements and restructuring its finances. Its technology matters, but long-term impact depends on whether the business can fund itself while scaling.
For Factorial, the evidence is more commercial than scientific. Its platform began with HR tasks and is expanding into payroll-related administration, expenses, and wider workflows for smaller businesses. The appeal is simple: fewer spreadsheets and fewer disconnected tools. The company says it reached one hundred million dollars in annual recurring revenue in twenty twenty-five. That’s a useful sign of customer demand, though it remains a company-reported figure.
Its real challenge is retaining clients across markets while adding enough functions to become essential, without turning into a complicated imitation of enterprise software. The remaining cases underline how varied transformation can be. Heura has to win repeat purchases for plant-based food through taste, price, and distribution, not mission alone.
Perk, formerly TravelPerk, wants to combine corporate travel and spending into a platform companies rely on every day. Supplier complexity and entrenched rivals make that difficult. Multiverse Computing is pursuing model-compression techniques inspired by advanced mathematics and quantum research. Its claim is not that it has solved quantum computing, but that some AI workloads may need less memory and computation.
That case demands specific benchmarks
That case demands specific benchmarks, independent validation, and paying customers. The common mistake is to treat funding, valuation, or public support as a scoreboard. They are inputs. They buy time, equipment, trials, hiring, and market expansion. Commercial traction means customers stay. Technical validation means a rocket launches, a treatment works in trials, or a benchmark stands up to scrutiny.
Industry change comes later, when those results scale with durable economics. Public money can be sensible in strategic, capital-heavy sectors, but it is not a substitute for adoption. So the useful map is simple: PLD Space needs repeatable launches. SpliceBio needs clinical proof. Wallbox needs financial durability. And the software, food, and AI companies need lasting customer value.
To explore this further, you can generate Five Cents episodes on The Economics of Small Satellite Launches and How Gene Therapy Reaches Difficult Diseases. And with that, you're up to speed in a few minutes.